Ann Intern Med:风湿病学:2023年你可能错过了什么

14天前 来源:Ann Intern Med

本文由小咖机器人翻译整理

期刊来源:Ann Intern Med

原文链接:https://doi.org/10.7326/M24-0678

摘要内容如下:

许多风湿病患者接受内科医生而不是风湿病学家的治疗。在此,我们注意到2023年发表的6项风湿病学研究的关键发现,这些研究为风湿病学以外的内科专家和专科医生提供了有价值的见解。第一项研究调查了低剂量糖皮质激素对类风湿性关节炎(RA)患者2年的影响,并对现有的关于糖皮质激素在这种情况下的风险的看法提出了质疑。第二项研究的重点是预防和治疗糖皮质激素诱导的骨质疏松症的最新指南。随着糖皮质激素的长期广泛使用,美国风湿病学会强调了评估骨折风险和适时开始药物治疗的重要性。第三项研究探索了甲氨蝶呤在治疗炎症性手骨关节炎中的潜在用途,提出了一种新的方法来管理这种具有挑战性的常见疾病。我们强调的第四篇文章的结果表明,在糖皮质激素剂量逐渐减少的过程中,Sarilumab有望作为风湿性多肌痛复发的辅助治疗。第五项研究评估了舌下含服环苯扎林治疗纤维肌痛,指出了潜在的益处和风险。最后,第六篇文章是一篇系统综述和荟萃分析,评估了生物仿制药和参考生物制剂在治疗RA患者中的治疗等效性。这些最新文献的知识将对临床医生有用,无论其专业是什么,他们都会照顾患有这些常见疾病的患者。

英文原文如下:

Abstracts

Many patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for preventing and treating glucocorticoid-induced osteoporosis. With the chronic and widespread use of glucocorticoids, the American College of Rheumatology emphasized the importance of assessing fracture risk and initiating pharmacologic therapy when appropriate. The third study explored the potential use of methotrexate in treating inflammatory hand osteoarthritis, suggesting a novel approach to managing this challenging and common condition. The results of the fourth article we highlight suggest that sarilumab has promise as an adjunct treatment of polymyalgia rheumatica relapse during glucocorticoid dosage tapering. The fifth study evaluated sublingual cyclobenzaprine for fibromyalgia treatment, noting both potential benefits and risks. Finally, the sixth article is a systematic review and meta-analysis that assessed the therapeutic equivalence of biosimilars and reference biologics in the treatment of patients with RA. Knowledge of this recent literature will be useful to clinicians regardless of specialty who care for patients with these commonly encountered conditions.

-----------分割线---------

点击链接:https://www.mediecogroup.com/community/user/vip/categories/ ,成为医咖会员,获取12项专属权益。

评论
请先登录后再发表评论
发表评论
下载附件需认证
为保证平台的学术氛围,请先完成认证,认证可免费享受基础会员权益
基础课程券2张
专属科研工作台
200积分
确认
取消
公众号
统计咨询
扫一扫添加小咖个人微信,立即咨询统计分析服务!
会员服务
SCI-AI工具
积分商城
意见反馈